Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial

Immunic Inc. (NASDAQ:IMUX) is one of the best penny stocks under $1 to buy now. On June 24, Immunic reported positive long-term open-label extension/OLE data from its Phase 2 EMPhASIS trial. The trial evaluated vidofludimus calcium (IMU-838), which is an orally available nuclear receptor-related 1 (Nurr1) activator, in patients with relapsing-remitting multiple sclerosis/RRMS.

The cumulative data from the EMPhASIS OLE period, which shows ~952 treatment years, further support the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and minimal treatment-emergent and serious adverse events. Importantly, no new safety signals have emerged during treatment durations extending up to 5.5 years. The Phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study that initially randomized 268 RRMS patients.

Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial

A closeup of pills in a pharmacy, representing the high quality medications of the company.

Vidofludimus calcium (IMU-838) is an orally administered investigational small molecule drug in late-stage clinical trials for multiple sclerosis. Its unique dual mode of action combines neuroprotective, anti-inflammatory, and anti-viral effects. It acts as a selective immune modulator by activating the neuroprotective transcription factor Nurr1, which provides direct and indirect neuroprotective benefits.

Immunic Inc. (NASDAQ:IMUX) is a biotechnology company that develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the US and Germany.

While we acknowledge the potential of IMUX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMUX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.